NASDAQ:REPL Replimune Group (REPL) Stock Forecast, Price & News $22.95 +3.96 (+20.85%) (As of 01:45 PM ET) Add Compare Share Share Today's Range$20.01▼$23.1350-Day Range$15.65▼$19.7052-Week Range$13.84▼$29.52Volume699,734 shsAverage Volume542,740 shsMarket Capitalization$1.33 billionP/E RatioN/ADividend YieldN/APrice Target$51.60 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Replimune Group MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside151.3% Upside$51.80 Price TargetShort InterestBearish17.04% of Float Sold ShortDividend StrengthN/ASustainability-1.28Upright™ Environmental ScoreNews Sentiment0.49Based on 11 Articles This WeekInsider TradingSelling Shares$1 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.57) to ($3.96) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.17 out of 5 starsMedical Sector358th out of 980 stocksBiological Products, Except Diagnostic Industry53rd out of 163 stocks 3.5 Analyst's Opinion Consensus RatingReplimune Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $51.80, Replimune Group has a forecasted upside of 151.3% from its current price of $20.61.Amount of Analyst CoverageReplimune Group has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted17.04% of the float of Replimune Group has been sold short.Short Interest Ratio / Days to CoverReplimune Group has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.Change versus previous monthShort interest in Replimune Group has recently increased by 2.75%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldReplimune Group does not currently pay a dividend.Dividend GrowthReplimune Group does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreReplimune Group has received a 69.41% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for Replimune Group is -1.28. Previous Next 2.5 News and Social Media Coverage News SentimentReplimune Group has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Replimune Group this week, compared to 2 articles on an average week.MarketBeat Follows3 people have added Replimune Group to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Replimune Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,003,634.00 in company stock.Percentage Held by Insiders23.80% of the stock of Replimune Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.83% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Replimune Group are expected to decrease in the coming year, from ($3.57) to ($3.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Replimune Group is -6.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Replimune Group is -6.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReplimune Group has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Replimune Group (NASDAQ:REPL) StockReplimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.Read More Receive REPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter. Email Address REPL Stock News HeadlinesJune 5, 2023 | americanbankingnews.comReplimune Group (NASDAQ:REPL) Shares Gap Up on Analyst UpgradeJune 5, 2023 | americanbankingnews.comReplimune Group (NASDAQ:REPL) Shares Gap Up Following Analyst UpgradeJune 5, 2023 | Edge On The Street (Ad)New "Mined in America" Lithium Opportunities?The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.June 5, 2023 | markets.businessinsider.comEF Hutton Remains a Buy on Replimune Group (REPL)June 5, 2023 | finance.yahoo.comReplimune Appoints Veleka R. Peeples-Dyer to its Board of DirectorsJune 5, 2023 | americanbankingnews.comHC Wainwright Increases Replimune Group (NASDAQ:REPL) Price Target to $51.00June 3, 2023 | tmcnet.comReplimune Presents RP1 Data from the IGNYTE anti-…June 3, 2023 | finance.yahoo.comReplimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingJune 5, 2023 | Edge On The Street (Ad)New "Mined in America" Lithium Opportunities?The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.June 1, 2023 | finance.yahoo.comReplimune to Present at the Jefferies Global Healthcare ConferenceMay 29, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on Replimune Group (REPL)May 26, 2023 | msn.comEF Hutton Reiterates Replimune Group (REPL) Buy RecommendationMay 26, 2023 | americanbankingnews.comFY2024 EPS Estimates for Replimune Group, Inc. (NASDAQ:REPL) Cut by WedbushMay 25, 2023 | finance.yahoo.comReplimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingMay 25, 2023 | americanbankingnews.comReplimune Group, Inc. (NASDAQ:REPL) Expected to Earn Q1 2024 Earnings of ($0.87) Per ShareMay 23, 2023 | markets.businessinsider.comBMO Capital Keeps Their Buy Rating on Replimune Group (REPL)May 22, 2023 | msn.comWedbush Reiterates Replimune Group (REPL) Outperform RecommendationMay 22, 2023 | americanbankingnews.comReplimune Group, Inc. (NASDAQ:REPL) Given Consensus Recommendation of "Buy" by AnalystsMay 20, 2023 | americanbankingnews.comJean M. Franchi Sells 11,351 Shares of Replimune Group, Inc. (NASDAQ:REPL) StockMay 20, 2023 | americanbankingnews.comReplimune Group, Inc. (NASDAQ:REPL) CEO Philip Astley-Sparke Sells 17,902 SharesMay 18, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Teva Pharmaceutical (TEVA) and Replimune Group (REPL)May 18, 2023 | marketwatch.comReplimune Group Chief Financial Officer Jean Franchi Resigns >REPLMay 18, 2023 | msn.comRecap: Replimune Group Q4 EarningsMay 18, 2023 | finance.yahoo.comReplimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate UpdateMay 17, 2023 | finance.yahoo.comIs a Surprise Coming for Replimune (REPL) This Earnings Season?May 9, 2023 | finance.yahoo.comReplimune to Participate in the Piper Sandler Spring Biopharma SymposiumApril 25, 2023 | americanbankingnews.comReplimune Group, Inc. (NASDAQ:REPL) Receives $51.67 Average Price Target from BrokeragesSee More Headlines REPL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REPL Company Calendar Last Earnings11/04/2021Today6/05/2023Next Earnings (Estimated)8/03/2023Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:REPL CUSIPN/A CIK1737953 Webwww.replimune.com Phone(781) 222-9600FaxN/AEmployees152Year Founded2015Price Target and Rating Average Stock Price Forecast$51.60 High Stock Price Forecast$70.00 Low Stock Price Forecast$34.00 Forecasted Upside/Downside+171.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-174,280,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-35.84% Return on Assets-31.39% Debt Debt-to-Equity Ratio0.09 Current Ratio17.52 Quick Ratio17.52 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.61 per share Price / Book1.98Miscellaneous Outstanding Shares57,780,000Free Float44,025,000Market Cap$1.10 billion OptionableNot Optionable Beta1.64 Key ExecutivesPhilip Astley-SparkeChief Executive Officer & DirectorRobert CoffinPresident & DirectorColin A. LoveChief Operating OfficerJean M. FranchiChief Financial Officer, Secretary & TreasurerKonstantinos XynosChief Medical OfficerKey CompetitorsImmunityBioNASDAQ:IBRXSana BiotechnologyNASDAQ:SANAInhibrxNASDAQ:INBXAdaptive BiotechnologiesNASDAQ:ADPTExscientiaNASDAQ:EXAIView All CompetitorsInsiders & InstitutionsAmeriprise Financial Inc.Sold 7,200 shares on 5/22/2023Ownership: 0.366%JPMorgan Chase & Co.Bought 10,518 shares on 5/18/2023Ownership: 0.288%New York State Common Retirement FundSold 6,700 shares on 5/18/2023Ownership: 0.038%Philip Astley-SparkeSold 17,902 sharesTotal: $323,131.10 ($18.05/share)Colin LoveSold 10,775 sharesTotal: $194,488.75 ($18.05/share)View All Insider TransactionsView All Institutional Transactions REPL Stock - Frequently Asked Questions Should I buy or sell Replimune Group stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" REPL shares. View REPL analyst ratings or view top-rated stocks. What is Replimune Group's stock price forecast for 2023? 5 Wall Street analysts have issued 12-month target prices for Replimune Group's shares. Their REPL share price forecasts range from $34.00 to $70.00. On average, they expect the company's stock price to reach $51.60 in the next year. This suggests a possible upside of 171.7% from the stock's current price. View analysts price targets for REPL or view top-rated stocks among Wall Street analysts. How have REPL shares performed in 2023? Replimune Group's stock was trading at $27.20 at the start of the year. Since then, REPL shares have decreased by 30.2% and is now trading at $18.99. View the best growth stocks for 2023 here. When is Replimune Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our REPL earnings forecast. How were Replimune Group's earnings last quarter? Replimune Group, Inc. (NASDAQ:REPL) issued its earnings results on Thursday, November, 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.05. What ETFs hold Replimune Group's stock? ETFs with the largest weight of Replimune Group (NASDAQ:REPL) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Loncar Cancer Immunotherapy ETF (CNCR), Horizon Kinetics Medical ETF (MEDX), ALPS Medical Breakthroughs ETF (SBIO), First Trust Innovation Leaders ETF (ILDR), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). What other stocks do shareholders of Replimune Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC). When did Replimune Group IPO? (REPL) raised $100 million in an initial public offering (IPO) on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO. What is Replimune Group's stock symbol? Replimune Group trades on the NASDAQ under the ticker symbol "REPL." Who are Replimune Group's major shareholders? Replimune Group's stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (9.70%), BlackRock Inc. (6.39%), State Street Corp (5.13%), BVF Inc. IL (3.78%), FMR LLC (2.04%) and Dimensional Fund Advisors LP (1.90%). Insiders that own company stock include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Pamela Esposito, Philip Astley-Sparke, Robert Coffin and Sushil Patel. View institutional ownership trends. How do I buy shares of Replimune Group? Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Replimune Group's stock price today? One share of REPL stock can currently be purchased for approximately $18.99. How much money does Replimune Group make? Replimune Group (NASDAQ:REPL) has a market capitalization of $1.10 billion. The company earns $-174,280,000.00 in net income (profit) each year or ($3.00) on an earnings per share basis. How many employees does Replimune Group have? The company employs 152 workers across the globe. How can I contact Replimune Group? Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The official website for the company is www.replimune.com. The company can be reached via phone at (781) 222-9600 or via email at ir@replimune.com. This page (NASDAQ:REPL) was last updated on 6/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.